Ascendis Pharma A/S (ASND)
ASND Stock Price Chart
Explore Ascendis Pharma A/S interactive price chart. Choose custom timeframes to analyze ASND price movements and trends.
ASND Company Profile
Discover essential business fundamentals and corporate details for Ascendis Pharma A/S (ASND) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Jan 2015
Employees
1.02k
Website
https://ascendispharma.comCEO
Jan Moller Mikkelsen
Description
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
ASND Financial Timeline
Browse a chronological timeline of Ascendis Pharma A/S corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is $1.27, while revenue estimate is $438.69m.
Earnings released on 7 May 2026
EPS came in at $0.32 surpassing the estimated $0.19 by +70.58%, while revenue for the quarter reached $284.92m , missing expectations by -7.77%.
Earnings released on 11 Feb 2026
EPS came in at -$0.64 falling short of the estimated -$0.06 by -966.67%, while revenue for the quarter reached $344.84m , beating expectations by +17.99%.
Earnings released on 12 Nov 2025
EPS came in at -$1.17 falling short of the estimated -$0.41 by -185.37%, while revenue for the quarter reached $250.22m , missing expectations by -17.31%.
Earnings released on 7 Aug 2025
EPS came in at -$0.93 surpassing the estimated -$1.42 by +34.51%, while revenue for the quarter reached $186.09m , missing expectations by -20.17%.
Earnings released on 1 May 2025
EPS came in at -$1.66 falling short of the estimated -$1.56 by -6.41%, while revenue for the quarter reached $110.67m , missing expectations by -27.89%.
Earnings released on 12 Feb 2025
EPS came in at -$0.68 surpassing the estimated -$1.20 by +43.33%, while revenue for the quarter reached $180.09m , beating expectations by +43.59%.
Earnings released on 14 Nov 2024
EPS came in at -$1.81 surpassing the estimated -$1.83 by +1.15%, while revenue for the quarter reached $63.43m , missing expectations by -14.45%.
Earnings released on 3 Sept 2024
EPS came in at -$2.05 falling short of the estimated -$1.54 by -33.12%, while revenue for the quarter reached $38.71m , beating expectations by +3.01%.
Earnings released on 2 May 2024
EPS came in at -$2.48 falling short of the estimated -$1.62 by -53.33%, while revenue for the quarter reached $103.02m , beating expectations by +11.54%.
Earnings released on 7 Feb 2024
EPS came in at -$1.66 surpassing the estimated -$2.19 by +24.14%, while revenue for the quarter reached $151.44m , beating expectations by +36.28%.
Earnings released on 7 Nov 2023
EPS came in at -$3.08 falling short of the estimated -$2.55 by -21.01%, while revenue for the quarter reached $50.67m , missing expectations by -8.41%.
Earnings released on 5 Sept 2023
EPS came in at -$2.35 surpassing the estimated -$2.68 by +12.31%, while revenue for the quarter reached $55.40m , beating expectations by +27.29%.
Earnings released on 27 Apr 2023
EPS came in at -$2.18 surpassing the estimated -$2.93 by +25.56%, while revenue for the quarter reached $36.52m , beating expectations by +41.63%.
Earnings released on 16 Feb 2023
EPS came in at -$3.96 falling short of the estimated -$2.74 by -44.53%, while revenue for the quarter reached $24.66m , beating expectations by +11.86%.
Earnings released on 2 Nov 2022
EPS came in at -$3.05 falling short of the estimated -$2.52 by -21.03%, while revenue for the quarter reached $14.93m , beating expectations by +9.82%.
Earnings released on 10 Aug 2022
EPS came in at -$1.50 surpassing the estimated -$2.19 by +31.46%, while revenue for the quarter reached $6.44m , beating expectations by +7.27%.
Earnings released on 11 May 2022
EPS came in at -$2.31 falling short of the estimated -$2.09 by -10.50%, while revenue for the quarter reached $7.55m , beating expectations by +43.76%.
Earnings released on 2 Mar 2022
EPS came in at -$2.06 surpassing the estimated -$2.57 by +20.09%, while revenue for the quarter reached $5.55m , beating expectations by +64.20%.
Earnings released on 10 Nov 2021
EPS came in at -$1.69 surpassing the estimated -$2.63 by +35.81%, while revenue for the quarter reached $1.29m , missing expectations by -24.14%.
Earnings released on 25 Aug 2021
EPS came in at -$3.01 falling short of the estimated -$2.75 by -9.45%, while revenue for the quarter reached $1.21m , missing expectations by -7.03%.
ASND Stock Performance
Access detailed ASND performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
